Loading...
•
Mar 31, 2024
Janux Q1 2024 Earnings Report
Janux reported financial results for Q1 2024 and provided a business update.
Key Takeaways
Janux Therapeutics reported a net loss of $14.8 million for the first quarter of 2024. The company's cash and cash equivalents and short-term investments totaled $651.8 million as of March 31, 2024. Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer and EGFR-TRACTr (JANX008) in solid tumors.
Enrollment is ongoing for PSMA-TRACTr (JANX007) in prostate cancer.
Enrollment is ongoing for EGFR-TRACTr (JANX008) in solid tumors.
An update on JANX007 data and doses selected for expansion cohorts is anticipated in 2H 2024.
The company held $651.8 million in cash and cash equivalents and short-term investments at the end of the first quarter 2024.
Revenue by Segment
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...